JP2024504257A - Ｉｐ４－４，６置換誘導体化合物 - Google Patents

Ｉｐ４－４，６置換誘導体化合物 Download PDF

Info

Publication number
JP2024504257A
JP2024504257A JP2023537515A JP2023537515A JP2024504257A JP 2024504257 A JP2024504257 A JP 2024504257A JP 2023537515 A JP2023537515 A JP 2023537515A JP 2023537515 A JP2023537515 A JP 2023537515A JP 2024504257 A JP2024504257 A JP 2024504257A
Authority
JP
Japan
Prior art keywords
compound
salt
inositol
room temperature
myo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504257A5 (https=
Inventor
フェレール，マリア・デル・マール ペレス
レイネス，ミゲル・ダビド フェレール
バッシッシ，モハンマド・フィラス
ロカ，カロリーナ サルセド
コマス，カルメ セラ
ルイス，フアン・ロレンソ カテナ
スルダビラ，アマデウ レバリア
カストロ，ホアキン オルテガ
ベスタルド，フアン ペレロ
Original Assignee
サニフィット・セラピューティクス・ソシエダッド・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サニフィット・セラピューティクス・ソシエダッド・アノニマ filed Critical サニフィット・セラピューティクス・ソシエダッド・アノニマ
Publication of JP2024504257A publication Critical patent/JP2024504257A/ja
Publication of JP2024504257A5 publication Critical patent/JP2024504257A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023537515A 2021-01-29 2022-01-31 Ｉｐ４－４，６置換誘導体化合物 Pending JP2024504257A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382075.6 2021-01-29
EP21382075.6A EP4036097A1 (en) 2021-01-29 2021-01-29 Ip4-4,6 substituted derivative compounds
PCT/EP2022/052164 WO2022162206A1 (en) 2021-01-29 2022-01-31 Ip4-4,6 substituted derivative compounds

Publications (2)

Publication Number Publication Date
JP2024504257A true JP2024504257A (ja) 2024-01-31
JP2024504257A5 JP2024504257A5 (https=) 2025-01-22

Family

ID=74732816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537515A Pending JP2024504257A (ja) 2021-01-29 2022-01-31 Ｉｐ４－４，６置換誘導体化合物

Country Status (13)

Country Link
US (1) US20240109924A1 (https=)
EP (2) EP4036097A1 (https=)
JP (1) JP2024504257A (https=)
KR (1) KR20230132811A (https=)
CN (1) CN116745304A (https=)
AR (1) AR124717A1 (https=)
AU (1) AU2022212601A1 (https=)
BR (1) BR112023014549A2 (https=)
CA (1) CA3202780A1 (https=)
IL (1) IL303825A (https=)
MX (1) MX2023008250A (https=)
TW (1) TW202239414A (https=)
WO (1) WO2022162206A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023551660A (ja) * 2020-11-20 2023-12-12 ヴィフォール （インターナショナル） アーゲー 石灰化関連腎臓病の治療をするためのイノシトールヘキサキスリン酸アナログ

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023313374A1 (en) * 2022-07-29 2025-02-13 Vifor (International) Ltd. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
EP0431197A1 (en) * 1989-06-28 1991-06-12 MITSUI TOATSU CHEMICALS, Inc. Myoinositol derivative and method of production thereof, and phosphorylating agent and its use
JPH11508240A (ja) * 1995-06-07 1999-07-21 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 膜透過性第２メッセンジャー
JP2007510710A (ja) * 2003-11-07 2007-04-26 ラボラトリオス、サニフィト、ソシエダッド、リミターダ 局所用のミオイノシトール６リン酸
JP2019504905A (ja) * 2015-12-11 2019-02-21 エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ 病理的結晶化に用いられるイノシトール誘導体
WO2019176693A1 (ja) * 2018-03-15 2019-09-19 国立大学法人広島大学 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755612A (en) * 1987-07-20 1988-07-05 Merck & Co., Inc. Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
JP6893037B2 (ja) 2015-12-11 2021-06-23 エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873355A (en) * 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
EP0431197A1 (en) * 1989-06-28 1991-06-12 MITSUI TOATSU CHEMICALS, Inc. Myoinositol derivative and method of production thereof, and phosphorylating agent and its use
JPH11508240A (ja) * 1995-06-07 1999-07-21 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 膜透過性第２メッセンジャー
JP2007510710A (ja) * 2003-11-07 2007-04-26 ラボラトリオス、サニフィト、ソシエダッド、リミターダ 局所用のミオイノシトール６リン酸
JP2019504905A (ja) * 2015-12-11 2019-02-21 エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ 病理的結晶化に用いられるイノシトール誘導体
WO2019176693A1 (ja) * 2018-03-15 2019-09-19 国立大学法人広島大学 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE COMMUNICATIONS, vol. 11(1), JPN6025046653, 2020, pages 721, ISSN: 0005747402 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023551660A (ja) * 2020-11-20 2023-12-12 ヴィフォール （インターナショナル） アーゲー 石灰化関連腎臓病の治療をするためのイノシトールヘキサキスリン酸アナログ

Also Published As

Publication number Publication date
AU2022212601A1 (en) 2023-07-06
BR112023014549A2 (pt) 2023-10-10
CN116745304A (zh) 2023-09-12
WO2022162206A1 (en) 2022-08-04
AU2022212601A9 (en) 2025-04-10
AR124717A1 (es) 2023-04-26
EP4284809A1 (en) 2023-12-06
CA3202780A1 (en) 2022-08-04
EP4036097A1 (en) 2022-08-03
MX2023008250A (es) 2023-07-26
IL303825A (en) 2023-08-01
US20240109924A1 (en) 2024-04-04
KR20230132811A (ko) 2023-09-18
TW202239414A (zh) 2022-10-16

Similar Documents

Publication Publication Date Title
US12012467B2 (en) Small molecule DCN1 inhibitors and therapeutic methods using the same
KR102536408B1 (ko) Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드
DE69600784T2 (de) Proteinkinase-C-Inhibitor
KR20120087878A (ko) 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
JP5976322B2 (ja) テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途
ES2628374T3 (es) Derivado de indanosulfamida novedoso
ES3014225T3 (en) Rapamycin derivatives
EP4089102A1 (en) Modulators of sortilin activity
JP2024504257A (ja) Ｉｐ４－４，６置換誘導体化合物
JP2012519193A5 (https=)
WO2018138085A1 (en) Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
JP2025525092A (ja) 異所性石灰化の治療、進行の阻害、および予防に使用するためのｉｐ４－４，６置換誘導体化合物
Wang et al. Synthesis and vasorelaxation evaluation of novel biphenyl–furocoumarin derivatives
EA050725B1 (ru) Замещенные производные соединений ip4-4,6
AU2023313051A1 (en) Ip5 substituted compounds
HK40094155A (zh) Ip4-4，6取代的衍生化合物
HK40123408A (zh) 用於治疗异位钙化、抑制进展和预防异位钙化的ip4-4，6取代的衍生物化合物
JP7829949B2 (ja) リン酸エステル基を含有する化合物、それを含有する医薬組成物、その調製方法、及びその使用
CA3161134A1 (en) Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds
RU2782469C2 (ru) Апоптоз-индуцирующие агенты
WO2023248010A2 (en) Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
EP4735466A1 (en) Htra1 inhibitors and uses thereof
TWI522358B (zh) 四氫咪唑并〔１，５－ａ〕吡衍生物的鹽，其製備方法及其在醫藥上的應用
EA052895B1 (ru) Агенты для индукции klf2 и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260227